TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2684452

Group type: EXPERIMENTAL
Intervention: Aqueous flunisolide
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Aqueous beclomethasone dipropionate
Number of subjects: 23

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 23
Study: 28683004

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate/70% isopropyl alcohol (CHG/IPA) followed by gum mastic liquid adhesive (GMLA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate/70% isopropyl alcohol (CHG/IPA) followed by liquid adhesive remover (LAR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2% chlorhexidine gluconate/70% isopropyl alcohol (CHG/IPA)
Number of subjects: 20
Study: 26209025

Group type: EXPERIMENTAL
Intervention: It's LiFe! monitoring and feedback tool + Self‐Management Support Program (SSP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self‐Management Support Program (SSP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study: 22924447

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 329
Study: 21482217

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 10/320 mg (intensive)
Number of subjects: 728

Group type: COMPARATOR
Intervention: Amlodipine/valsartan 5/160 mg (moderate)
Number of subjects: 728
Study: 18626761

Group type: EXPERIMENTAL
Intervention: Animated video
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Video of self
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Video of a familiar person engaged with an immersive virtual reality (VR) game
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Immersion of self in the VR game
Number of subjects: 42
Study: 17079992

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) coadministered with lopinavir/ritonavir (LPV/r)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) with lopinavir/ritonavir (LPV/r)
Number of subjects: 24
Study: 15715034

Group type: EXPERIMENTAL
Intervention: Massage therapy (two 20 min sessions per week for 16 weeks)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (self-administered sessions on the same schedule)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (standard prenatal care)
Number of subjects: 84
Study: 11280830

Group type: EXPERIMENTAL
Intervention: Gabexate mesilate 1 g/day continuous infusion up to postoperative day 4
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gabexate mesilate 1 g/day continuous infusion plus octreotide 0.1 mg every 8 hours for 5 days
Number of subjects: 50
Study: 10322862

Group type: EXPERIMENTAL
Intervention: Tongxinluo capsule (TXLC), 4 capsules, three times daily
Number of subjects: 492

Group type: COMPARATOR
Intervention: Shuxin oral liquor (SXOL), 20 ml, two times daily
Number of subjects: 492
Study: 8233513

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (VR) for 8 weeks followed by 8 weeks of home VR exercises
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control treatment (isometric strengthening exercises) for 8 weeks followed by 8 weeks of VR
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both groups (A and B) at 16-week post-test
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Self-reported Dizziness Handicap Inventory scores
Number of subjects: 8
Study: 3691557

Group type: EXPERIMENTAL
Intervention: Training group (A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (B)
Number of subjects: 44
Study: 30157768

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Control group (without DM)
Number of subjects: 1800
Study: 27522247

Group type: COMPARATOR
Intervention: Biopsy GS 6
Number of subjects: 796

Group type: COMPARATOR
Intervention: Biopsy GS 7(-)
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Biopsy GS 7(+)
Number of subjects: 796
Study: 25479285

Group type: EXPERIMENTAL
Intervention: Text messaging (daily for 2 weeks, alternate days for 2 weeks, weekly thereafter for 22 weeks)
Number of subjects: 303

Group type: COMPARATOR
Intervention: No text messaging (control group)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Text messaging
Number of subjects: 303
Study: 22715822

Group type: EXPERIMENTAL
Intervention: 3% thyme essential oil antifungal cream
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10% chamomile extract cream
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 24
Study: 20028815

Group type: EXPERIMENTAL
Intervention: Telbivudine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Entecavir
Number of subjects: 44
Study: 18360262

Group type: EXPERIMENTAL
Intervention: Low tacrolimus exposure
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard tacrolimus exposure
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study: 16137280

Group type: EXPERIMENTAL
Intervention: Individualized social activity intervention (ISAI) for 1 to 2 hours for 21 consecutive days
Number of subjects: 147
Study: 12169173

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SIT) with standardized Dermatophagoides pteronyssinus extract for 3 years
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no SIT)
Number of subjects: 29
Study: 9926749

Group type: EXPERIMENTAL
Intervention: Bedside Percutaneous (BP) tracheostomy
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bedside Open (BO) tracheostomy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Open tracheostomy in the operating room (OR)
Number of subjects: 24
Study: 7771482

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Alkylating agents
Number of subjects: 69

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 69
Study: 2297456

Group type: EXPERIMENTAL
Intervention: 300 mg aspirin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 600 mg aspirin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 6153835

Group type: EXPERIMENTAL
Intervention: Corticosteroid ointments (20 tested)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Corticosteroid creams (19 tested)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydrocortisone preparations (tested with occlusion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Other corticosteroid preparations (tested with and without occlusion)
Number of subjects: 12
Study: 30700068

Group type: EXPERIMENTAL
Intervention: Exercise Therapy (ET)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Manipulation Therapy (MT)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Exercise and Manipulation Therapy (EMT)
Number of subjects: 51
Study: 28658431

Group type: EXPERIMENTAL
Intervention: Prone position 2
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 33

Group type: COMPARATOR
Intervention: Other positions (Fowler's, supine, left lateral)
Number of subjects: 33
Study: 26071836

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC) with 3 cycles of 5-minute inflation to 200 mmHg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control procedure with 3 cycles of 5-minute inflation to 10 mmHg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RIPC and Control procedures
Number of subjects: 20
Study: 24913818

Group type: EXPERIMENTAL
Intervention: Broccoli sprout beverage providing daily doses of 600 μmol glucoraphanin and 40 μmol sulforaphane
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study: 22368023

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted radical gastrectomy (LAG group)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Conventional open gastrectomy (OG group)
Number of subjects: 255
Study: 19729908

Group type: EXPERIMENTAL
Intervention: High cut-off (HCO) membranes
Number of subjects: 8

Group type: COMPARATOR
Intervention: High-flux membranes
Number of subjects: 8
Study: 18090001

Group type: EXPERIMENTAL
Intervention: Continuous low‐flow hemofiltration (n = 8) or hemodiafiltration (n = 11)
Number of subjects: 19
Study: 16054252

Group type: EXPERIMENTAL
Intervention: Intra-arterial acetylcholine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intra-arterial nitroprusside
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ratio between acetylcholine and nitroprusside
Number of subjects: 63

Group type: COMPARATOR
Intervention: Healthy elderly group
Number of subjects: 63

Group type: COMPARATOR
Intervention: Atherosclerotic vascular disease group
Number of subjects: 63
Study: 14760893

Group type: EXPERIMENTAL
Intervention: Nelfinavir/nevirapine (1250/200 mg twice daily)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Ritonavir/saquinavir (400/400 mg twice daily)
Number of subjects: 233
Study: 10643677

Group type: EXPERIMENTAL
Intervention: High-fat diet (60% of energy fat)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Reduced-fat diet (30% of energy fat)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Endurance training (12 months)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Well-trained group
Number of subjects: 27
Study: 9025128

Group type: EXPERIMENTAL
Intervention: Active compression-decompression cardiopulmonary resuscitation (ACD-CPR)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard manual CPR (S-CPR)
Number of subjects: 220
Study: 2060563

Group type: EXPERIMENTAL
Intervention: lormetazepam 0.5 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: lormetazepam 1 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45
Study: 6637861

Group type: EXPERIMENTAL
Intervention: Treatment group 1
Number of subjects: 2

Group type: COMPARATOR
Intervention: Treatment group 2
Number of subjects: 2
Study: 30648524

Group type: EXPERIMENTAL
Intervention: Combined glucosamine hydrochloride plus chondroitin sulfate (GH+CS) 1500 mg + 1200 mg daily for 6 months
Number of subjects: 189

Group type: COMPARATOR
Intervention: Celecoxib 200 mg daily for 6 months
Number of subjects: 189
Study: 30576794

Group type: EXPERIMENTAL
Intervention: Tanezumab treatment with NSAIDs <90 days (limited NSAID users)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Tanezumab treatment with NSAIDs ≥90 days (chronic NSAID users)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (OA patients without the biomarker phenotype)
Number of subjects: 139
Study: 28871849

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dietary Intervention (DIET)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Resistance Training plus Diet (RT+DIET)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 40
Study: 27630954

Group type: EXPERIMENTAL
Intervention: 2% povidone iodine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 30
Study: 25124577

Group type: EXPERIMENTAL
Intervention: Microlux/DL device
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Microlux/DL device with toluidine blue
Number of subjects: 599

Group type: COMPARATOR
Intervention: Conventional Oral Examination (COE)
Number of subjects: 599
Study: 22250063

Group type: EXPERIMENTAL
Intervention: Flavonoid-enriched chocolate (27 g/day, containing 850 mg flavan-3-ols and 100 mg isoflavones)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 18805590

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 175
Study: 17625113

Group type: EXPERIMENTAL
Intervention: Epoetins (specific types not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional data analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phase plotting analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantification of notional instability of patient responses
Number of subjects: 0
Study: 15805374

Group type: EXPERIMENTAL
Intervention: Tobacco intervention (30-second clinician advice, 10-minute interactive computer program, 5-minute motivational interview, up to two 10-minute booster sessions)
Number of subjects: 2526

Group type: COMPARATOR
Intervention: Control intervention (5-minute motivational intervention to promote increased consumption of fruits and vegetables)
Number of subjects: 2526

Group type: EXPERIMENTAL
Intervention: Tobacco intervention
Number of subjects: 2526
Study: 10212711

Group type: EXPERIMENTAL
Intervention: PCEA (parturient-controlled epidural analgesia) - bolus 5 ml, lockout 15 minutes
Number of subjects: 40

Group type: COMPARATOR
Intervention: CIEA (continuous infusion epidural analgesia) - 8 ml/h
Number of subjects: 40
Study: 7832129

Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator, anistreplase, or both (exact dosage and duration not specified)
Number of subjects: 382
Study: 2078983

Group type: EXPERIMENTAL
Intervention: Levodopa (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol (single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 532796

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Tolmetin
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31951261

Group type: EXPERIMENTAL
Intervention: eGFR ≤60 mL/min/1.73 m2
Number of subjects: 19391

Group type: EXPERIMENTAL
Intervention: eGFR = 45 mL/min/1.73 m2
Number of subjects: 19391

Group type: EXPERIMENTAL
Intervention: eGFR <75 mL/min/1.73 m2
Number of subjects: 19391

Group type: COMPARATOR
Intervention: eGFR ≥75 mL/min/1.73 m2
Number of subjects: 19391

Group type: EXPERIMENTAL
Intervention: Younger individuals (45 years)
Number of subjects: 19391

Group type: EXPERIMENTAL
Intervention: Older individuals (65 years)
Number of subjects: 19391

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 19391
Study: 30663038

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (30-70 l.min-1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard flow-rate facemask (15 l.min-1)
Number of subjects: 40
Study: 27914309

Group type: EXPERIMENTAL
Intervention: Sensorimotor training with a new device (5-6 weeks)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Subjective assessment of balance
Number of subjects: 72
Study: 23910386

Group type: EXPERIMENTAL
Intervention: Nano-hydroxyapatite-coated mini-implants
Number of subjects: 25

Group type: COMPARATOR
Intervention: Commercially pure titanium mini-implants
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both implant surfaces (nano-hydroxyapatite-coated and cp titanium)
Number of subjects: 25
Study: 23362969

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg early induction regimen (weeks 0, 1, 2, 4)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg monthly induction regimen (weeks 0, 4, 8)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Fixed-interval secukinumab (150 mg at weeks 12 and 24)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Start-of-relapse secukinumab (150 mg at visits at which a start of relapse was observed)
Number of subjects: 404
Study: 21143704

Group type: EXPERIMENTAL
Intervention: Gabapentin (starting dose 300 mg once daily to a target of 900 mg daily)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 20092743

Group type: EXPERIMENTAL
Intervention: Damage Control Surgery (DCS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Early Total Care (ETC)
Number of subjects: 90
Study: 17284910

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-containing glass ionomer cement
Number of subjects: 50
Study: 14972420

Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) at standard dose (600mg orally twice daily; SD Group; n=110)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) at double dose (1200mg orally twice daily; DD Group; n=114)
Number of subjects: 224

Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) at standard dose (SD Group)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) at double dose (DD Group)
Number of subjects: 224
Study: 11856901

Group type: EXPERIMENTAL
Intervention: Hypericum (900 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hypericum (1800 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Amitriptyline (25 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 9748684

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 100
Study: 7884329

Group type: EXPERIMENTAL
Intervention: Chiropractic adjustments (high velocity, short lever adjustments of the spine)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham adjustment (using an Activator at a nontension setting)
Number of subjects: 46
Study: 3067754

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 29569389

Group type: EXPERIMENTAL
Intervention: SeR-Se-Ly (1 tablet daily for 6 months)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Tadalafil 5 mg (1 tablet daily for 6 months)
Number of subjects: 427
Study: 28224232

Group type: EXPERIMENTAL
Intervention: Traumeel (Tr14)
Number of subjects: 0
Study: 26917026

Group type: EXPERIMENTAL
Intervention: Ilizarov fixation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LRS fixation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Rail fixators
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ring fixators
Number of subjects: 32
Study: 24273971

Group type: EXPERIMENTAL
Intervention: Danzhi Xiaoyao Pill (DXP) in addition to Metformin and Diane-35
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metformin and Diane-35 (Control Group B)
Number of subjects: 60
Study: 21948897

Group type: EXPERIMENTAL
Intervention: Active-priming rTMS (4-8 Hz; 400 pulses, at 90% of motor threshold)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham-priming stimulation followed by low-frequency rTMS (1-Hz; 900 pulses at 110% of motor threshold)
Number of subjects: 40
Study: 18296979

Group type: EXPERIMENTAL
Intervention: Warm-up only
Number of subjects: 64

Group type: COMPARATOR
Intervention: Warm-up plus static stretching
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Warm-up plus dynamic stretching
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Warm-up plus dynamic flexibility
Number of subjects: 64
Study: 16530767

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 100 mg/day on days 1-5 of the menstrual cycle (group 1)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 100 mg/day on days 5-9 of the menstrual cycle (group 2)
Number of subjects: 78
Study: 12679683

Group type: EXPERIMENTAL
Intervention: Open Reduction Internal Fixation (ORIF)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Nonoperative management
Number of subjects: 424
Study: 14676042

Group type: EXPERIMENTAL
Intervention: Clioquinol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10219029

Group type: EXPERIMENTAL
Intervention: Perpendicular peripheral corneal incision (blow-off valve)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Oblique peripheral corneal incision (water-tight)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control eyes (unoperated)
Number of subjects: 42
Study: 7652983

Group type: EXPERIMENTAL
Intervention: Local anaesthesia with 20 ml of 1% lidocaine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intravenous anaesthesia with pethidine/diazepam
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 68
Study: 2504566

Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms twice daily
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 799551

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 0
Study: 31247980

Group type: COMPARATOR
Intervention: Conventional cocoa (CC) 15 g in 200 mL of semi-skimmed milk containing 19.80 mg of flavanols
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa (CC-PP) 25 g in 200 mL of semi-skimmed milk containing 68.25 mg of flavanols
Number of subjects: 13
Study: 28842449

Group type: EXPERIMENTAL
Intervention: Informed consent by patients themselves
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Informed consent by proxy
Number of subjects: 1005
Study: 25474080

Group type: EXPERIMENTAL
Intervention: Nurse-led educational telephone intervention (two scheduled calls over six weeks)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Nurse-led educational telephone intervention
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (standard care including a self-management plan)
Number of subjects: 73
Study: 24112817

Group type: COMPARATOR
Intervention: Gait training on a treadmill with placebo transcranial stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gait training on a treadmill with active transcranial stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mobility training with virtual reality and placebo transcranial stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobility training with virtual reality and active transcranial stimulation
Number of subjects: 0
Study: 21873708

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg/day
Number of subjects: 2950

Group type: COMPARATOR
Intervention: Warfarin (dose-adjusted, target INR 2.0-3.0)
Number of subjects: 2950
Study: 20329617

Group type: EXPERIMENTAL
Intervention: Needle-pricking (NP) applied mainly on bilateral points of sacral plexus and para-vertebra L1, every 5 days for 45 days.
Number of subjects: 122

Group type: COMPARATOR
Intervention: L-dopa and ephedrine, orally 1 hour before sexual intercourse for 45 days.
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Needle-pricking (NP)
Number of subjects: 122

Group type: COMPARATOR
Intervention: L-dopa and ephedrine
Number of subjects: 122
Study: 18332595

Group type: EXPERIMENTAL
Intervention: HYB exercise regimen (volitional contraction against applied electrical stimulation)
Number of subjects: 13

Group type: COMPARATOR
Intervention: ELS Group (electrical stimulation delivered to the biceps brachii and triceps brachii with limb fixed)
Number of subjects: 13